By Rahul T. Pandit, MD; Parag A. Majmudar, MD
    ASCRS 2013 Annual Meeting
    Refractive Mgmt/Intervention

    In this interview from the 2013 American Society of Cataract and Refractive Surgery Annual Meeting, Dr. Parag Majmudar discusses his standard protocol for using adjunctive mitomycin C (MMC) in photorefractive keratectomy (PRK). In general, Dr. Majmudar reserves the use of MMC for eyes with high to moderate risk of developing corneal haze, or ablation depths greater than 75 µm. Developed over the course of 14 years, Dr. Majmudar's standard regimen is 0.02% MMC applied for 12 seconds. While he doesn't believe altering the concentration to be of any clinical benefit, he does consider increasing the application time if patients present with preexisting haze. The use of MMC carries a separate informed consent process, and Dr. Majmudar recommends talking to patients about its toxicity despite little evidence to suggest MMC applied to the cornea poses long-term risk to ocular or systemic health.